Novartis drug Exjade® first treatment approved by FDA for chronic iron overload in patients with non-transfusion-dependent thalassemia

Novartis drug Exjade® first treatment approved by FDA for chronic iron overload in patients with non-transfusion-dependent thalassemia

Jan 23, 2013
Source URL: https://qa1.novartis.us/us-en/news/media-releases/novartis-drug-exjade-first-treatment-approved-fda-chronic-iron-overload-patients-non-transfusion-dependent-thalassemia-0

List of links present in page
  1. https://qa1.novartis.us/us-en/us-en/news/media-releases/novartis-drug-exjade-first-treatment-approved-fda-chronic-iron-overload-patients-non-transfusion-dependent-thalassemia-0